| Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary … M Decramer, A Anzueto, E Kerwin, T Kaelin, N Richard, G Crater, ... The Lancet Respiratory Medicine 2 (6), 472-486, 2014 | 309 | 2014 |
| Once-daily umeclidinium/vilanterol 125/25 μg therapy in COPD: a randomized, controlled study B Celli, G Crater, S Kilbride, R Mehta, M Tabberer, CJ Kalberg, A Church Chest 145 (5), 981-991, 2014 | 192 | 2014 |
| Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes A Anzueto, GT Ferguson, G Feldman, K Chinsky, A Seibert, A Emmett, ... COPD: Journal of Chronic Obstructive Pulmonary Disease 6 (5), 320-329, 2009 | 187 | 2009 |
| Transient orientation of linear DNA molecules during pulsed-fleld gel electrophoresis G Holzwarth, CB McKee, S Steiger, G Crater Nucleic acids research 15 (23), 10031-10044, 1987 | 124 | 1987 |
| Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD NA Hanania, GD Crater, AN Morris, AH Emmett, DM O’Dell, ... Respiratory medicine 106 (1), 91-101, 2012 | 122 | 2012 |
| Research in progress: medical research council united kingdom refractory asthma stratification programme (RASP-UK) LG Heaney, R Djukanovic, A Woodcock, S Walker, JG Matthews, ... Thorax 71 (2), 187-189, 2016 | 102 | 2016 |
| Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol DB Badesch, MD McGOON, RJ Barst, VF Tapson, LJ Rubin, FM Wigley, ... The Journal of Rheumatology 36 (10), 2244-2249, 2009 | 101 | 2009 |
| Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials F Maltais, S Singh, AC Donald, G Crater, A Church, AH Goh, JH Riley Therapeutic Advances in Respiratory Disease 8 (6), 169-181, 2014 | 90 | 2014 |
| Characterization of airway inflammation in patients with COPD using fractional exhaled nitric oxide levels: a pilot study JF Donohue, N Herje, G Crater, K Rickard International journal of chronic obstructive pulmonary disease, 745-751, 2014 | 83 | 2014 |
| Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibility ER Bleecker, A Emmett, G Crater, K Knobil, C Kalberg Pulmonary pharmacology & therapeutics 21 (4), 682-688, 2008 | 75 | 2008 |
| A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD JF Donohue, A Anzueto, J Brooks, R Mehta, C Kalberg, G Crater Respiratory medicine 106 (7), 970-979, 2012 | 73 | 2012 |
| Disease severity and symptoms among patients receiving monotherapy for COPD MT Dransfield, W Bailey, G Crater, A Emmett, DM O'Dell, B Yawn Primary Care Respiratory Journal 20 (1), 46-53, 2011 | 68 | 2011 |
| Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients M Decramer, F Maltais, G Feldman, J Brooks, S Harris, R Mehta, G Crater Respiratory Physiology & Neurobiology 185 (2), 393-399, 2013 | 59 | 2013 |
| The acceleration of linear DNA during pulsed‐field gel electrophoresis G Holzwarth, KJ Platt, CB McKee, RW Whitcomb, GD Crater Biopolymers: Original Research on Biomolecules 28 (6), 1043-1058, 1989 | 59 | 1989 |
| Prevalence of COPD among symptomatic patients in a primary care setting B Yawn, D Mannino, T Littlejohn, G Ruoff, A Emmett, I Raphiou, G Crater Current medical research and opinion 25 (11), 2671-2677, 2009 | 56 | 2009 |
| 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial G Feldman, RR Walker, J Brooks, R Mehta, G Crater Pulmonary Pharmacology & Therapeutics 25 (6), 465-471, 2012 | 50 | 2012 |
| Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial DL Kelleher, RS Mehta, BM Jean-Francois, AF Preece, J Blowers, ... PLoS One 7 (12), e50716, 2012 | 47 | 2012 |
| Effect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD MT Dransfield, JR Cockcroft, RR Townsend, HO Coxson, SS Sharma, ... Respiratory medicine 105 (9), 1322-1330, 2011 | 45 | 2011 |
| A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19 D Singh, M Bogus, V Moskalenko, R Lord, EJ Moran, GD Crater, ... European Respiratory Journal 58 (4), 2021 | 38 | 2021 |
| Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study R Mehta, D Kelleher, A Preece, S Hughes, G Crater International Journal of Chronic Obstructive Pulmonary Disease, 159-167, 2013 | 38 | 2013 |
